Comparison of genomic DNA sequences from human and mouse revealed a new apolipoprotein (APO) gene (APOAV ) located proximal to the well-characterized APOAI/CIII/AIV gene cluster on human 11q23. Mice expressing a human APOAV transgene showed a decrease in plasma triglyceride concentrations to one-third of those in control mice; conversely, knockout mice lacking Apoav had four times as much plasma triglycerides as controls. In humans, single nucleotide polymorphisms (SNPs) across the APOAV locus were found to be significantly associated with plasma triglyceride levels in two independent studies. These findings indicate that APOAV is an important determinant of plasma triglyceride levels, a major risk factor for coronary artery disease.
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Plasma lipid levels are a major determinant of cardiovascular disease susceptibility (1) . Members of the apolipoprotein gene family have been shown to play a significant role in determining an organism's lipid profile, with alterations in the level or structure of these molecules leading to abnormal lipid levels and atherosclerosis susceptibility (2) (3) (4) (5) (6) . The apolipoprotein gene cluster (APOAI/CIII/ AIV ) on human 11q23 (7) is a well-studied region known to influence plasma lipid parameters in humans. Defined mutations in this cluster dramatically affect plasma lipid profiles in both humans and mice (2, (8) (9) (10) (11) (12) , and common sequence polymorphisms in this interval have been implicated as contributing to severe hypertriglyceridemia (13) (14) (15) (16) . Genome sequencing efforts produced finished sequence throughout the human APOAI/ CIII/AIV region, thereby providing a resource to better understand the genomic structure of this locus (17) . To facilitate the identification of evolutionarily conserved sequences with potential function near this cluster, we determined the sequence of ϳ200 kilobase pairs (kbp) of orthologous mouse DNA and compared the mouse and human sequences ( Fig. 1) (18) . On the basis of extended interspecies sequence horizontally. Above each panel arrows correspond to known genes and their orientation with each exon depicted by a box (gene names are indicated above each arrow). The VISTA graphical plot displays the level of homology between human and the orthologous mouse sequence. Human sequence is represented on the x axis and the percent similarity with the mouse sequence is plotted on the y axis (ranging from 50 to 100% identity).
conservation about 30 kbp proximal to the APOAI/CIII/AIV gene cluster, we identified a genomic interval that contained a putative apolipoprotein-like gene (APOAV ) (Fig. 1B) . The presence of publicly available mouse expressed-sequence tags (ESTs) matching the mouse genomic sequence suggested that the interval was transcribed. The annotation of mouse ESTs on the mouse genomic sequence identified four exons containing a 1107-base pair (bp) open reading frame. The predicted 368 -amino acid sequence showed significant homology to various known apolipoproteins, with the strongest similarity to mouse Apoaiv (24% identity and 49% similarity). Examination of the orthologous human genomic sequence indicated a genomic structure similar to the mouse region and predicted an open reading frame encoding a 366 -amino acid protein with high sequence homology to mouse Apoav (71% identity and 78% similarity), as well as human APOAIV (27% identity, 48% similarity). Protein structure analyses predicted several amphipathic helical domains and an NH 2 -terminal signal peptide in both human and mouse APOAV, characteristic features of lipid-binding apolipoproteins (19, 20) . To determine the expression pattern of APOAV, we hybridized Northern blots containing mRNA from several different human and mouse tissues with APOAV cDNA probes from human and mouse, respectively (Fig. 2, A and B) . Transcripts about 1.3 and 1.9 kilobases (kb) in length were identified predominantly in liver tissue from both species. The full-length sequences of mouse cDNAs indicated the two transcripts in mice are likely the result of alternative polyadenylation (21, 22) .
To assess the function of APOAV, we generated mice overexpressing human APOAV as well as mice lacking Apoav, through standard mouse transgenic and gene knockout technologies (Fig. 2 , C to E) (23-25). Upon comparing these two groups, we observed dramatic, but opposite effects on plasma triglyceride levels (26). Human APOAV transgenic mice were created by using a 26-kbp Xho I fragment predicted to contain only human APOAV, and this genomic transgene was expressed in liver, as is the endogenous gene (Fig. 2C ). These transgenic mice had levels of plasma triglyceride that were about one-third of those of control littermates [0.32 Ϯ 0.11 (S.D.) mg/ml versus 0.90 Ϯ 0.29; t test, P Ͻ 0.0001] (Fig. 3A) . Similar data were obtained from a second independent founder line (27). Apoav knockout mice were generated by deleting the three exons predicted to encode Apoav (Fig. 2D) . Despite the lack of Apoav transcript ( Fig.  2E) , mice homozygous for the deletion were born at the expected Mendelian rate and appeared normal. In contrast to the decreased triglyceride levels noted in APOAV transgenics, Apoav knockout mice had about four times as much plasma triglyceride as their wild-type littermates [1.53 Ϯ 0.77 (SD) mg/ ml versus 0.37 Ϯ 0.12; t test, P Ͻ 0.001) (Fig. 3B) . Characterization of lipoprotein particles by fast-protein liquid chromatography (FPLC) and gradient-gel electrophoresis (GGE) revealed that levels of very low density lipoprotein (VLDL) particles were increased in the homozygous knockout mice and decreased in the transgenic mice com- Fig. 2 . APOAV expression in humans and wild-type, transgenic, and knockout mice (52) . (A) A mouse Apoav cDNA probe was hybridized to a multi-tissue RNA blot from wild-type mice. Each lane contained one of eight mouse tissues (Clontech, Palo Alto, California): 1, heart; 2, brain; 3, spleen; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; or 8, testis. (B) A human APOAV cDNA probe was hybridized to an RNA blot containing eight human tissues (Clontech,): 1, heart; 2, brain; 3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; or 8, pancreas. (C) A human-specific APOAV cDNA probe was hybridized to total RNA blots from human APOAV transgenic mice and controls. Lane assignments are as follows: 1 and 5, transgenic liver; 2 and 6, transgenic intestine; 3 and 7, wild-type liver; and 4 and 8, wild-type intestine. (D) A diagram of the targeting construct used to generate Apoav-deficient mice. Homology arms were designed to delete the coding exons of the gene (depicted by black boxes). Properly targeted embryonic stem cells were identified by using an external 3Ј probe, which detects a 17-kb Eco RI fragment wild-type allele and a 10-kb Eco RI fragment upon targeting (27) . ( 
transgenic versus control). (B) Mice lacking
Apoav compared with mixed 129Sv/C57BL6 strain controls littermates (n ϭ 13 for wildtype, ϩ/ϩ; n ϭ 22 for heterozygotes, ϩ/-; n ϭ 10 for homozygous knockouts, -/-; Student's t test, **P Ͻ 0.001 for wild-type versus knockout). Error bars correspond to the standard deviation for both graphs. No differences were found in HDL-cholesterol levels in transgenic or knockout mice compared with controls (27).
pared with controls (28). VLDL levels in a heterozygous knockout mouse were intermediate between the homozygous knockout and control mouse. VLDL peak particle size as assessed by GGE and FPLC peak elution volume was similar in all animals (29). Analysis of FPLC elution volumes demonstrated mouse Apoav immunoreactivity in VLDL and HLD fractions.
The observed changes in plasma triglyceride levels in Apoav knockout and transgenic mice were directly opposite those previously reported in Apociii knockout and transgenic mice (9, 10) . The Apoav knockouts in our study displayed about a 400% increase in plasma triglycerides compared with the 30% decrease noted in Apociii knockouts, whereas APOAV transgenics showed decreased triglyceride levels compared with the increase reported in APOCIII transgenics. Accordingly, we examined the effect of altered APOAV expression on Apociii levels. Differences were found in apociii protein but not transcript levels in both APOAV transgenic and knockout animals; Apociii levels were increased ϳ90% in Apoav knockouts and decreased ϳ40% in APOAV transgenics. Because alterations in APOAV expression lead to changes in Apociii protein levels, the effect on triglycerides we observed may be mediated through Apociii. The fact that APOAV transgenic mice have one-half the triglycerides that the previously described Apociii knockout mice have indicates (10) that changes in Apociii alone cannot explain the entire effect of APOAV. In addition to APOCIII, the overexpression of several human apolipoprotein transgenes has been shown to increase triglyceride levels in mice (8, 9, (30) (31) (32) (33) , whereas only the APOAV transgene leads to decreased triglycerides, suggesting another mechanism behind this effect.
The observation of significant lipid abnormalities in mice overexpressing and lacking Apoav led us to explore the relationship between DNA sequence polymorphisms in the gene and plasma lipid levels in humans. To serve as genetic markers for association studies, we identified single nucleotide polymorphisms (SNPs) across and surrounding the human APOAV locus (34) (Fig. 1A) . Four markers with relatively high minor allele frequencies (Ͼ8%) were obtained. Three of the SNPs were separated by 3 kbp within APOAV (SNP1 to SNP3); the fourth SNP (SNP4) was located ϳ11 kbp upstream of the gene (Fig. 1A) . These markers were scored in about 500 random unrelated normolipidemic Caucasian individuals who had been phenotyped for numerous lipid parameters before and after consumption of high-and low-fat diets (35). We found significant associations between both plasma triglyceride levels and VLDL mass and the three neighboring SNPs (SNPs 1 to 3) within APOAV but not with the distant upstream SNP4 (Figs.  1A and 4A) . Specifically, the minor allele of each of these SNPs (SNPs 1 to 3) was associated with higher triglyceride levels independent of diet. Independent analysis of each of these SNPs (SNPs 1 to 3) revealed plasma triglyceride levels were 20 to 30% higher in individuals having one minor allele compared with individuals homozygous for the major allele (Fig. 4A) . Analysis of SNP allele frequencies in more than 4) . Individuals (n ϭ 501) were genotyped, and the number of successfully scored individuals is indicated. Notation: 1,1 is homozygous for the major allele; 1,2 is heterozygous for the major and minor alleles. Three individuals were homozygous for the SNP3 minor allele and had a mean plasma triglyceride level of 210 Ϯ 155 mg/dl. Because of the small number of individuals, these data were excluded from the analysis. All sites were found to be in Hardy-Weinberg equilibrium (53) . The minor allele frequency for each SNP (SNPs 1 to 4) was 9.1, 8.4, 9.2 and 36.3%, respectively. Not shown is the lack of association between each of the four SNPs and IDL-, LDL-, HDL-mass, ApoAI, and ApoB levels [P Ͼ 0.05, (54) ]. (B) Pair-wise measure of linkage disequilibrium (ԽDЈԽ) was calculated for all combinations of SNPs as previously described (55) . A ԽDЈԽ value of 1 indicates complete linkage disequilibrium between two markers. (C) A summary of SNP3 genotyping data from an independent set of individuals stratified based on triglyceride levels. P values were determined by chi-square analysis. BMI, body mass index; TG, plasma triglyceride level (mg/dl Ϯ SD). Similar analysis stratifying the original population did result in statistically significant differences in the genotype distribution when we used a similar analysis (P ϭ 0.044).
1000 chromosomes revealed that the three neighboring SNPs (SNPs 1 to 3) in APOAV were in significant linkage disequilibrium that does not extend to SNP4 (located ϳ11kb upstream of APOAV ) (Fig. 4B) . This finding supports the existence of a common haplotype in the APOAV region influencing plasma triglyceride levels (Figs. 1A and 4B) . Furthermore, studies in this population found no significant association of triglyceride levels with an Sst I polymorphism in APOCIII (located ϳ40 kbp upstream of APOAV ) (Fig. 1A) which has been previously associated with hypertriglyceridemia (15, 16, 28, 36) . This finding indicates that the APOCIII Sst I polymorphism is not a marker for the metabolic effect defined by the APOAV haplotype.
Genetic association studies have frequently proved difficult to reproduce. Therefore, we performed a second human association study with one SNP (SNP3) in an independently ascertained cohort using a different experimental design (37). SNP3 was chosen for genotyping in this study based on its strong association in our first study and its apparent complete linkage disequilibrium with the other two associated SNPs (SNPs 1 and 2) (Fig. 4, A and B) . In the second study, we examined the allele frequencies for SNP3 in an unrelated group of Caucasians stratified according to plasma triglyceride levels (Fig. 4C) . The two groups represented 161 individuals with triglyceride levels in the top 10th percentile and 298 individuals from the bottom 10th percentile. A significant overrepresentation of the heterozygous genotype was found in individuals with high compared with low plasma triglyceride levels (21.7% versus 6.7%, respectively), thereby validating the association of APOAV polymorphisms and triglyceride levels in a second cohort. When the cohort was stratified based on gender, an even more pronounced overrepresentation of the heterozygous genotype was found in males with high compared with low plasma triglyceride levels (29.9% versus 4.2%, respectively).
Despite the previous availability of sequence in the human APOAI/CIII/AIV genomic interval, we only recently were directed to a novel gene (APOAV ) by comparison of human and mouse sequence, illustrating the power of comparative sequence analysis to prioritize potential functional regions of the genome. APOAV represents a fourth member of the clinically important apolipoprotein gene cluster on human 11q23. Our human and mouse data, both when taken independently and combined, indicate an important role for APOAV in plasma triglyceride homeostasis. Although previous data have associated the APOCIII locus with extremely high plasma triglyceride levels in humans, our study indicates that the APOAV genomic interval represents an independent influence on this important lipid parameter in the general population. These results suggest the possible use of APOAV polymorphisms as prognostic indicators for hypertriglyceridemia susceptibility and the focus on APOAV modulation as a potential strategy to reduce this known cardiovascular disease risk factor. APOCIII, and APOAIV mRNA sequences with the BLAST algorithm (38) identified a genomic bacterial artificial chomosome (BAC) clone containing the complete APOAI/CIII/AIV gene cluster (GenBank accession number AC007707). 18. Orthologous mouse genomic DNA was isolated from a pooled BAC library by using the polymerase chain reaction (PCR) with mouse primers: apoAI-F1-5Ј-GAG-GATGTGGAGCTCTACCGC-3Ј and apoAI-R1-5Ј-CTGT- quence (GenBank accession number AC007707) indicated that the entire human APOAV gene, but not neighboring genes, was contained within a 26-kbp Xho I DNA fragment (corresponding to about 1 to 27 kbp in Fig. 1B) . BAC DNA corresponding to the clone sequenced from this region was prepared by standard alkaline lysis with a chromatography column (Qiagen, Valencia, CA), digested with the restriction enzyme Xho I and separated in 1% agarose by pulsed-field gel electrophoresis. The 26-kbp Xho I DNA fragment containing human apoAV was purified by using QiaEx II gel purification (Qiagen), adjusted to a final concentration of ϳ1 ng/ml and microinjected into fertilized FVB inbred mouse eggs by using standard procedures (23). Two founder transgenic mice were identified as determined by PCR (polymer chain reaction) amplification using primers hApoAV-intrn-F1-5Ј-CCCGCTGCAGTCCCCA-GAAT-3Ј and hApoAV-intrn-R1-5Ј-CAGGGTCGAG-GGCTCT TGTCCT-3Ј. Each founder line was expanded by breeding to isogenic FVB strain mice (The Jackson Laboratory, Bar Harbor, ME). The targeting construct to delete mouse Apoav was built by using PCR products amplified from BAC-RPCI-23-175F2 DNA (BACPAC Resources, Children's Hospital Oakland Research Institute) (18). The first homology arm was PCR-amplified by using primers containing introduced 5Ј restriction sites for Xba I and Eco RI, respectively: mAV-Xba I-F1-5Ј-TGACTCTAGATACCC-T TGGTCCCATGT TCCAGAT-3Ј and mAV-Eco RI-R1-5Ј-CAT TGAAT TCGACAAGAGAAAGACGGGGCTCAAG-3Ј. The resulting 4.2-kbp PCR product was cloned into pXL-Topo (Invitrogen), DNA prepared by standard alkaline lysis (Qiagen) and digested with Eco RI according to the manufacturer's recommendations (New England Biolabs, Beverly, MA). A 4.2-kbp Eco RI fragment was gel-purified and cloned into the Eco RI site of the pPN2T vector to yield pPN2T-Arm1 (24). Clones were screened by PCR for inserts using the above-described primers, and positive clones were sequenced for proper orientation. The second homology arm was PCR-amplified with primers mAV-NotI-F4-5Ј-TATGACTGCGGCCGC-CACCAATCCCACATCTAAGCATCT-3Ј, containing an introduced 5Ј Not I restriction site, and mAV-XhoI-R3-5Ј-GCTCGGT TCTGGGCACAGAGA-3Ј. The resulting 5.3-kbp PCR product containing an endogenous internal Xho I restriction site was digested with Not I and Xho I to yield a 5.1-kbp fragment, which was directionally cloned into the Xho I and Not I sites of the pPN2T-Arm1 vector to yield final vector pPN2T-apoAV-KO. Embryonic stem cells from the 129/SvJ strain (Incyte Genomics, Palo Alto, CA) were electroporated with 20 g of the Not I linearized targeting construct and subsequently selected in 200 g/ml G418 and 0.5 g/ml 1-2Ј-deoxy-2Ј-fluoro-␤-D-arabinofuranosyl-5-iodouracil for 8 days. Individual clones were isolated, expanded, and screened by Southern blot analysis. The external 3Ј probe was amplified by PCR with primers mApoAV-3Јprobe-F2-5Ј-CT TGAGGATGGGCATCAGCT-GTAT-3Ј and mApoAV-3Јprobe-R2-5Ј-GCTCACTAA-CAGCGCTCT TGCCT-3Ј. Targeted clones were injected into C57BL/6 blastocysts and chimeric males were bred to C57BL/6 females ( Jackson Laboratory). Agouti offspring were tested for germ line transmission of the targeted allele by PCR with primers specific to the neomycin gene (NeoF1-5Ј-CT T T TTGTCAAGACCGAC-CTG-3Ј and NeoR1-5Ј-AATATCACGGGTAGCCAACGC-3Ј) and heterozygous animals were intercrossed to obtain homozygous deletion animals for the mouse Apoav locus. Offspring were genotyped with PCR primers designed to the neomycin gene (described above) and with primers contained within the Apoav deleted interval (mApoAV-F2-5Ј-ACAGT TGGAGCAAAGGCGT-GAT-3Ј and mApoAV-R2-5Ј-CT TGCTCGAAGCTGC-CT T TCAG-3Ј). 26. Blood samples were collected after a 5-hour fast by retro-orbital bleeding by using heparinized microhematocrit tubes. Total cholesterol and triglyceride concentrations were measured by using enzymatic methods on a Gilford System 3500 analyzer (Gilford Instruments, Oberlin, OH) (45 (50, 51) . Plasma lipid and lipoprotein measurements were performed as previously described (50, 51) . In addition, on the high-and low-fat diets, total lipoprotein mass was measured by analytic ultracentrifugation (50, 51) . 36. Of the 501 individuals in the original study, 388 were successfully genotyped by PCR amplification for the Sst I polymorphism as previously described (16, 28) . 37. To genotype the C/T SNP3 polymorphisms upstream of APOAV, oligonucleotides AV6-F-5Ј-GAT TGAT TCAA-GATGCAT T TAGGAC-3Ј and AV6-R-5Ј-CCCC-AGGAACTGGAGCGAAATT were used to amplify a 187-bp fragment from genomic DNA. The penultimate base in AV6-R was changed to T to create a Mse I site (TTAA) in the common allele. The PCR reactions were performed in 20 l volumes containing 50 mmol/liter KCl, 10 mmol/liter tris ( pH 8.3), 1.5 mmol/liter MgCl 2 , 0.2 mmol/liter of each dNTP, 1 U of Taq DNA polymerase, and 200 pmol/liter of each primer. DNA was amplified under the following conditions: initial denaturation of 96°C for 2 min, followed by 32 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 30 s, and a final step at 72°C for 3 min. PCR product (20 l) was digested with 10 U of Mse I (New England Biolabs) at 37°C for 3 hours. The PCR products were size-fractionated on 3% agarose gels, stained with ethidium bromide, and visualized on an ultraviolet transilluminator.
